12 January 2009: NorDiag has appointed Isogen Life Science as exclusive distributor in the field of infectious diseases for the Netherlands, Belgium, Luxemburg and Spain.

Isogen Life Science provides a wide range of instruments, reagents and consumables in the areas of cell biology, molecular biology and biochemistry. The products are used by biotechnology companies, clinical laboratories and leading research institutes. The company`s headquarters are in De Meern, the Netherlands, with sales offices in St-Pieters-Leeuw (Belgium) and Barcelona (Spain).

Mårten Wigstøl, CEO in NorDiag, comments: `We are very pleased to have the opportunity to work with an established player which infrastructure covers several countries, such as Isogen Life Science. The fact that they purchased our `Bullet` instrument upon signing of the deal shows commitment and great confidence in our products`.

Hans Beijersbergen van Henegouwen, CEO of Isogen Life Science added: `For the last couple of years we have built up an extensive sales and service expertise in DNA sample preparation on robotic systems. Nordiag`s range of products will fit very nicely in our ambition to further extend our expansion into the clinical market.`

NorDiag has started to penetrate the European market with its CE IVD labeled instruments and reagents, NorDiag has already established a solid foothold and market share in Scandinavia and the strategy is to use the Scandinavian market as a reference market for further commercialization and geographic expansion.   Isogen Life Science is expected to give a major contribution to this process, with their network, competence and industry knowledge.

Contact:
CEO Mårten Wigstøl             
Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here